Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
Irving
Julie A E
JA
Leukaemia Research Fund Molecular Pharmacology Laboratory, School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle, Newcastle, UK. j.a.e.irving@ncl.ac.uk
O'Brien
Stephen
S
Lennard
Anne L
AL
Minto
Lynne
L
Lin
Feng
F
Hall
Andrew G
AG
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D019008:Drug Resistance, Neoplasm; D005091:Exons; D016044:Fusion Proteins, bcr-abl; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl